Jazz Pharmaceuticals PLC
NASDAQ:JAZZ

Watchlist Manager
Jazz Pharmaceuticals PLC Logo
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
Watchlist
Price: 126.67 USD 1.25% Market Closed
Market Cap: 7.7B USD
Have any thoughts about
Jazz Pharmaceuticals PLC?
Write Note

Intrinsic Value

The intrinsic value of one JAZZ stock under the Base Case scenario is 360.43 USD. Compared to the current market price of 126.67 USD, Jazz Pharmaceuticals PLC is Undervalued by 65%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

JAZZ Intrinsic Value
360.43 USD
Undervaluation 65%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Jazz Pharmaceuticals PLC

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for JAZZ cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about JAZZ?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Jazz Pharmaceuticals PLC

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Jazz Pharmaceuticals PLC

Provide an overview of the primary business activities
of Jazz Pharmaceuticals PLC.

What unique competitive advantages
does Jazz Pharmaceuticals PLC hold over its rivals?

What risks and challenges
does Jazz Pharmaceuticals PLC face in the near future?

Has there been any significant insider trading activity
in Jazz Pharmaceuticals PLC recently?

Summarize the latest earnings call
of Jazz Pharmaceuticals PLC.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Jazz Pharmaceuticals PLC.

Provide P/S
for Jazz Pharmaceuticals PLC.

Provide P/E
for Jazz Pharmaceuticals PLC.

Provide P/OCF
for Jazz Pharmaceuticals PLC.

Provide P/FCFE
for Jazz Pharmaceuticals PLC.

Provide P/B
for Jazz Pharmaceuticals PLC.

Provide EV/S
for Jazz Pharmaceuticals PLC.

Provide EV/GP
for Jazz Pharmaceuticals PLC.

Provide EV/EBITDA
for Jazz Pharmaceuticals PLC.

Provide EV/EBIT
for Jazz Pharmaceuticals PLC.

Provide EV/OCF
for Jazz Pharmaceuticals PLC.

Provide EV/FCFF
for Jazz Pharmaceuticals PLC.

Provide EV/IC
for Jazz Pharmaceuticals PLC.

Show me price targets
for Jazz Pharmaceuticals PLC made by professional analysts.

What are the Revenue projections
for Jazz Pharmaceuticals PLC?

How accurate were the past Revenue estimates
for Jazz Pharmaceuticals PLC?

What are the Net Income projections
for Jazz Pharmaceuticals PLC?

How accurate were the past Net Income estimates
for Jazz Pharmaceuticals PLC?

What are the EPS projections
for Jazz Pharmaceuticals PLC?

How accurate were the past EPS estimates
for Jazz Pharmaceuticals PLC?

What are the EBIT projections
for Jazz Pharmaceuticals PLC?

How accurate were the past EBIT estimates
for Jazz Pharmaceuticals PLC?

Compare the revenue forecasts
for Jazz Pharmaceuticals PLC with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Jazz Pharmaceuticals PLC and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Jazz Pharmaceuticals PLC against its competitors.

Analyze the profit margins
(gross, operating, and net) of Jazz Pharmaceuticals PLC compared to its peers.

Compare the P/E ratios
of Jazz Pharmaceuticals PLC against its peers.

Discuss the investment returns and shareholder value creation
comparing Jazz Pharmaceuticals PLC with its peers.

Analyze the financial leverage
of Jazz Pharmaceuticals PLC compared to its main competitors.

Show all profitability ratios
for Jazz Pharmaceuticals PLC.

Provide ROE
for Jazz Pharmaceuticals PLC.

Provide ROA
for Jazz Pharmaceuticals PLC.

Provide ROIC
for Jazz Pharmaceuticals PLC.

Provide ROCE
for Jazz Pharmaceuticals PLC.

Provide Gross Margin
for Jazz Pharmaceuticals PLC.

Provide Operating Margin
for Jazz Pharmaceuticals PLC.

Provide Net Margin
for Jazz Pharmaceuticals PLC.

Provide FCF Margin
for Jazz Pharmaceuticals PLC.

Show all solvency ratios
for Jazz Pharmaceuticals PLC.

Provide D/E Ratio
for Jazz Pharmaceuticals PLC.

Provide D/A Ratio
for Jazz Pharmaceuticals PLC.

Provide Interest Coverage Ratio
for Jazz Pharmaceuticals PLC.

Provide Altman Z-Score Ratio
for Jazz Pharmaceuticals PLC.

Provide Quick Ratio
for Jazz Pharmaceuticals PLC.

Provide Current Ratio
for Jazz Pharmaceuticals PLC.

Provide Cash Ratio
for Jazz Pharmaceuticals PLC.

What is the historical Revenue growth
over the last 5 years for Jazz Pharmaceuticals PLC?

What is the historical Net Income growth
over the last 5 years for Jazz Pharmaceuticals PLC?

What is the current Free Cash Flow
of Jazz Pharmaceuticals PLC?

Discuss the annual earnings per share (EPS)
trend over the past five years for Jazz Pharmaceuticals PLC.

Business Breakdown

Jazz Pharmaceuticals PLC is a dynamic biopharmaceutical company that specializes in developing and commercializing innovative products to address unmet medical needs, particularly in the areas of sleep medicine and neurology. Founded in 2003 and headquartered in Dublin, Ireland, Jazz has successfully built a diverse portfolio of therapies that include treatments for rare and complex conditions like narcolepsy, which affects sleep quality and overall quality of life. The company's flagship product, Xyrem, has seen robust market success, driving revenue growth and allowing Jazz to expand its research and development efforts across multiple therapeutic areas. In recent years, Jazz has capitali...

Read More
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Jazz Pharmaceuticals PLC

Current Assets 4.4B
Cash & Short-Term Investments 2.6B
Receivables 723.6m
Other Current Assets 1B
Non-Current Assets 7.9B
PP&E 253.6m
Intangibles 6.9B
Other Non-Current Assets 662.8m
Current Liabilities 1B
Accounts Payable 85.4m
Accrued Liabilities 858m
Other Current Liabilities 86.5m
Non-Current Liabilities 7.1B
Long-Term Debt 6.1B
Other Non-Current Liabilities 973.9m
Efficiency

Earnings Waterfall
Jazz Pharmaceuticals PLC

Revenue
4B USD
Cost of Revenue
-424.2m USD
Gross Profit
3.6B USD
Operating Expenses
-2.9B USD
Operating Income
703.7m USD
Other Expenses
-240.5m USD
Net Income
463.2m USD

Free Cash Flow Analysis
Jazz Pharmaceuticals PLC

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

In the third quarter of 2024, Jazz Pharmaceuticals achieved over $1.05 billion in revenue, a 9% growth year-over-year, primarily driven by major products Xywav and Epidiolex, which saw a 14% increase. The company reaffirmed its full-year revenue guidance of $4 billion to $4.1 billion, with a projected oncology revenue of $1.08 billion to $1.13 billion. Meanwhile, the upcoming PDUFA date of November 29 for zanidatamab aims to secure approval for second-line biliary tract cancer. Recent trial results for Zepzelca indicate a significant opportunity for expansion into first-line therapy, positioning Jazz for continued growth in the oncology sector.

What is Earnings Call?
Fundamental Scores

JAZZ Profitability Score
Profitability Due Diligence

Jazz Pharmaceuticals PLC's profitability score is 57/100. The higher the profitability score, the more profitable the company is.

57/100
Profitability
Score

Jazz Pharmaceuticals PLC's profitability score is 57/100. The higher the profitability score, the more profitable the company is.

JAZZ Solvency Score
Solvency Due Diligence

Jazz Pharmaceuticals PLC's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Positive Net Debt
Average D/E
50/100
Solvency
Score

Jazz Pharmaceuticals PLC's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

JAZZ Price Targets Summary
Jazz Pharmaceuticals PLC

Wall Street analysts forecast JAZZ stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for JAZZ is 180.54 USD with a low forecast of 129.28 USD and a high forecast of 241.5 USD.

Lowest
Price Target
129.28 USD
2% Upside
Average
Price Target
180.54 USD
43% Upside
Highest
Price Target
241.5 USD
91% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for JAZZ?

Click here to dive deeper.

Dividends

Jazz Pharmaceuticals PLC
does not pay dividends
Shareholder Yield

Current shareholder yield for JAZZ is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

JAZZ Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

JAZZ News

Other Videos

Profile

Jazz Pharmaceuticals PLC Logo
Jazz Pharmaceuticals PLC

Country

Ireland

Industry

Pharmaceuticals

Market Cap

7.7B USD

Dividend Yield

0%

Description

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. The company is headquartered in Dublin, Dublin and currently employs 3,200 full-time employees. The company went IPO on 2012-01-18. The firm is focused on developing and commercializing products that address unmet medical needs. The firm has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. The firm's lead marketed products include Xyrem (sodium oxybate oral solution) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze for the treatment of acute lymphoblastic leukemia (ALL), and Defitelio (defibrotide) for the treatment of severe hepatic veno-occlusive disease (VOD). The firm also commercializes Prialt, an intrathecally administered infusion of ziconotide, approved by the FDA for the management of severe chronic pain in patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies or intrathecal morphine.

Contact

DUBLIN
DUBLIN
Fifth Fl, Waterloo Exchange, Waterloo Road
+35316347800.0
www.jazzpharma.com

IPO

2012-01-18

Employees

3 200

Officers

Co-Founder, Chairman & CEO
Mr. Bruce C. Cozadd
President & COO
Ms. Renee D. Gala
Senior VP & Chief Accounting Officer
Ms. Patricia Carr
Executive VP & Chief Legal Officer
Ms. Neena M. Patil J.D.
Executive VP, Chief Medical Officer and Global Head of Research & Development
Dr. Robert Iannone M.D.
Executive VP & CFO
Mr. Philip L. Johnson
Show More
VP & Head of Investor Relations
Ms. Andrea N. Flynn Ph.D.
Executive VP & Chief People Officer
Ms. Heidi Manna
Senior Vice President of Sleep & CNS Medicine
Dr. Jed Black M.D.
Executive VP & Chief Commercial OfficerChief Commercial Officer
Ms. Samantha Pearce
Show Less

See Also

Discover More
What is the Intrinsic Value of one JAZZ stock?

The intrinsic value of one JAZZ stock under the Base Case scenario is 360.43 USD.

Is JAZZ stock undervalued or overvalued?

Compared to the current market price of 126.67 USD, Jazz Pharmaceuticals PLC is Undervalued by 65%.

Back to Top